NZCity NewsLinks -

Finance

28 Apr 2024

Search

AFT,Massey Ventures,Gilles McIndoe to develop scar treatmen
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces it is to begin the development of a topical treatment for keloid and hypertrophic scarring with Massey Ventures, the commercialization company of Massey University

AFT - Maxigesic IV launched in the United States
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announces Maxigesic IV®, the patented intravenous form of its family of pain relief medicines, has today been launched in the US by its licensee Hikma Pharmaceuticals

AFT Pharma reports growth and global expansion
AFT Pharmaceuticals (NZX:AFT, ASX:AFP) today reports financial results for the six months to the end of September 2023 showing continued strong growth led by sales of over-the-counter medicines in Australasia and rising demand in International and Asian m

AFT Orphan Pharmaceuticals judgment
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) advises of the release yesterday evening by the High Court at Auckland of its judgment upholding in part claims by PBL Solutions Limited (PBL) against AFT, and dismissing others

CBD - Eqalis Cannabis-Based Ingredient Successfully Verified
Cannasouth Limited, (NZX:CBD), is pleased to announce that Eqalis Pharmaceuticals Ltd’s’ first cannabis-based ingredient has been successfully verified by the Medicinal Cannabis Agency (Agency) as meeting the New Zealand minimum quality standa

AFT - US FDA sets PDUFA date for Maxigesic IV
AFT Pharmaceuticals today announces the US Food and Drug Administration has set 17 October 2023 as the date by which it expects to respond to AFT’s application to register Maxigesic IV in the US

AFT Crystawash reg'n in China and new licencing agreements
AFT gains first product registration in China with Crystawash Extend and extends Maxigesic IV licensing

AFT announces Maxigesic IV® distribution agreement for nine
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed an exclusive. Licensing and distribution agreement for Maxigesic® IV, the intravenous form of its patented pain relief medicine, for nine countries in Eastern Europe

AFT makes further progress in international markets
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today provides an update on recent progress it has made in international markets

AFT broadens R&D pipeline with new product candidate
AFT Pharmaceuticals (ASX: AFP, NZX: AFT) today announces that it has entered into a partnership with one of its research and development partners, Belgium’s Hyloris Pharmaceuticals. to develop a novel locally acting product for the treatment of Burn

AFT’s Crystaderm antiseptic approved for sale in China
AFT Pharmaceuticals (ASX: AFP, NZX: AFT) today announces its first aid antiseptic cream Crystaderm has been approved for sale in China, the world’s second largest healthcare market

AFT - Retirement of Jon Lamb
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Jon Lamb today retired from the board following his announcement at the ASM that he would be stepping down once a new independent director had been appointed.

AFT - Jon Lamb intention to retire
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Jon Lamb has announced his intention to retire as a director of the company, following the recruitment and appointment of a replacement independent director to the Board

AFT Pharmaceuticals to announce full year results on Monday
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release on Monday May 22 2023 its full year results for the year ended March 31 2023. The release will be issued at around 09:00

AFT submits Maxigesic IV packaging data to the US FDA
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has submitted to the US Food and Drug Administration (FDA) data the regulator requested as it considers registration of the company’s patented intravenous pain relief medicine Maxigesic IV